Markets:

Overview

News

Currencies

International

Treasuries

Seagen Inc. - Common Stock (NQ:SGEN)

N/A UNCHANGED

Last Price Updated: 4:00 PM EST, Dec 13, 2023 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Seagen Inc. - Common Stock

< Previous 1 2

...

11 12 13 14 15 16 17 18 Next >

Seagen to Present at the Morgan Stanley 19th Annual Global Healthcare Conference

September 09, 2021

From Seagen Inc.

Via Business Wire

Seagen to Highlight Research From 16 Presentations Across Multiple Tumor Types at ESMO 2021

September 08, 2021

From Seagen Inc.

Via Business Wire

A Look Into Seagen's Price Over Earnings ↗

August 24, 2021

In the current market session, Seagen Inc. (NASDAQ:SGEN) is trading at $165.17, after a 0.24% drop. However, over the past month, the stock increased by 14.36%, and...

Via Benzinga

Week In Review: RemeGen Out-Licenses Rights For HER2 ADC To Seagen In $2.6 Billion Deal ↗

August 14, 2021

Yantai's RemeGen out-licensed global rights (ex-Asia) for its novel HER2-targeted ADC to Seagen in a $2.6 billion deal. Seagen, an antibody conjugate company, will pay $200 million upfront and up to...

Via Talk Markets

Earnings Scheduled For July 29, 2021 ↗

July 29, 2021

Companies Reporting Before The Bell • Smith & Nephew (NYSE:SNN) is projected to report earnings for its second quarter. • Cohen & Co (AMEX:COHN) is...

Via Benzinga

Earnings Scheduled For April 29, 2021 ↗

April 29, 2021

Companies Reporting Before The Bell • OSI Systems (NASDAQ:OSIS) is estimated to report quarterly earnings at $1.33 per share on revenue of $290.51 million. •...

Via Benzinga

Seagen Bets On China's ADC In $2.6B Cancer Deal ↗

August 09, 2021

Seagen Inc (NASDAQ: SGEN) and RemeGen Co Ltd have entered into an exclusive worldwide licensing agreement to develop and commercialize disitamab vedotin...

Via Benzinga

Seagen and RemeGen Announce Exclusive Worldwide License and Co-Development Agreement for Disitamab Vedotin

August 09, 2021

From Seagen Inc.

Via Business Wire

Seattle Genetics (SGEN) Q2 2021 Earnings Call Transcript ↗

July 30, 2021

SGEN earnings call for the period ending June 30, 2021.

Via The Motley Fool

Topics Earnings

Seagen Reports Second Quarter 2021 Financial Results

July 29, 2021

From Seagen Inc.

Via Business Wire

Astellas - Seagen's PADCEV Wins Full FDA Approval And Expanded Label In Tough-To-Treat Urothelial Cancer ↗

July 12, 2021

The FDA granted full approval and a label expansion for Seagen Inc (NASDAQ: SGEN) - Astellas Pharma Inc's (OTC: ALPMF) PADCEV to treat...

Via Benzinga

The Daily Biotech Pulse: Merck's Disappointing Q2, Atreca Falls On Data, FDA Nod For Viatris, Nuvalent, Icosavax IPOs ↗

July 29, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 28) AbbVie Inc. (NYSE: ABBV)...

Via Benzinga

The Week Ahead In Biotech (July 25-31): Big Pharma Earnings, Iterum FDA Decision, Alzheimer's Conference, IPOs and More ↗

July 25, 2021

Biotech stocks rebounded in the week ended July 23, thanks to the broader market strength. The sector also benefitted from the optimism that was set in motion by the solid start...

Via Benzinga

U.S. FDA Grants Regular Approval and Expands Indication for PADCEV® (enfortumab vedotin-ejfv) for Patients with Locally Advanced or Metastatic Urothelial Cancer

July 09, 2021

From Seagen Inc.

Via Business Wire

Seagen to Host Conference Call and Webcast Discussion of Second Quarter 2021 Financial Results on July 29, 2021

July 08, 2021

From Seagen Inc.

Via Business Wire

Updated Analysis Show Seagen's Tukysa Extended Median OS to Two Years with Benefits Maintained in Breast Cancer ↗

June 03, 2021

Seagen Inc (NASDAQ: SGEN) has announced that improvements in overall survival (OS) and progression-free survival (PFS) were maintained with long-term follow-up...

Via Benzinga

Seagen Announces Long-Term Results from TUKYSA® (tucatinib) Pivotal Trial in Patients with HER2-Positive Breast Cancer During the Virtual Scientific Program of the 2021 ASCO Annual Meeting

June 03, 2021

From Seagen Inc.

Via Business Wire

Seagen to Present at the Goldman Sachs 42nd Annual Global Healthcare Conference

June 02, 2021

From Seagen Inc.

Via Business Wire

The Week Ahead In Biotech: ASCO Presentations Front And Center, FDA Decisions Due For Scynexis, Liminal And Alkermes ↗

May 31, 2021

After having declined through the first half of the week, biotech stocks staged a recovery to close higher in the trading week ended May 28. Broader market sentiment and company-...

Via Benzinga

Seagen and Astellas Announce Updated Results from Two Trials of PADCEV® (enfortumab vedotin-ejfv) in Patients with Locally Advanced or Metastatic Urothelial Cancer Not Eligible for Cisplatin Chemotherapy

May 19, 2021

From Seagen Inc.

Via Business Wire

Got $5,000? These 3 Growth Stocks Are Trading Near Their 52-Week Lows ↗

May 12, 2021

Although they have been struggling recently, these stocks remain attractive buys over the long term.

Via The Motley Fool

Stocks That Hit 52-Week Lows On Friday ↗

April 30, 2021

Friday morning saw 14 companies set new 52-week lows. Points of Interest: Lufax Holding (NYSE:LU) was the largest, in terms of market cap, to set a new 52-week low...

Via Benzinga

Seattle Genetics (SGEN) Q1 2021 Earnings Call Transcript ↗

April 30, 2021

SGEN earnings call for the period ending March 31, 2021.

Via The Motley Fool

Topics Earnings

Recap: Seagen Q1 Earnings ↗

April 29, 2021

Shares of Seagen (NASDAQ:SGEN) decreased in after-market trading after the company reported Q1 results. Quarterly Results Earnings per share were up 31.63% over the past year to...

Via Benzinga

Seagen Reports First Quarter 2021 Financial Results

April 29, 2021

From Seagen Inc.

Via Business Wire

The Daily Biotech Pulse: Athenex, NeoGenomics And Amryt In M&A Mix, European Nod For Roche's Cancer Immunotherapy, Earnings Deluge Continues ↗

May 05, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 4) AbbVie Inc. (NYSE: ABBV)...

Via Benzinga

The Daily Biotech Pulse: Clinical Setback For Adverum, Galera Posts Data Readout, Moderna To Invest In Vaccine Manufacturing, Decision Day For Ardelyx ↗

April 29, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs April 28) Axonics, Inc. (NASDAQ:...

Via Benzinga

Seagen to Showcase Data from Growing Oncology Portfolio During Virtual Scientific Program of the 2021 ASCO Annual Meeting

April 29, 2021

From Seagen Inc.

Via Business Wire

Seattle Genetics's Earnings Outlook ↗

April 28, 2021

Seattle Genetics (NASDAQ:SGEN) announces its next round of earnings this Thursday, April 29. Here is Benzinga's everything-that-matters guide for this Thursday's Q1 earnings...

Via Benzinga

The Week Ahead In Biotech (April 25-May 1): FDA Decisions For Sol-Gel, Protalix Bio, Ardelyx ↗

April 24, 2021

Biopharma stocks came back from the weakness seen in the first two sessions to close the week ended April 23 higher. Johnson & Johnson (NYSE: JNJ) and Roche Holding AG (OTC:...

Via Benzinga

< Previous 1 2

...

11 12 13 14 15 16 17 18 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Seagen Inc. - Common Stock (NQ:SGEN)

All News about Seagen Inc. - Common Stock

Starting at $3.75/week.

Subscribe Today